4[1]Seidenman P.Methotrexate-the relationship between dose and clinical effect[J].Br J Rheumatol,1993,32(8):751
5[2]Albertioni F,Rask C,Eksborg S,et al.Evaluation of clinical assays for measuring high-dose methotrexate in plasma[J].Clinical Chemistry.1996,42(1):39
6[3]Treon SP,Chabner BA.Concepts in use of high-dose methotrexate therapy[J].Clinical Chemistry,1996,42(pt2):1322-1329
7[4]Grigg A.Folic Acid rescue after methotrexate[J].Bone Marrow Transplant.1993,11(3):1251
8[5]Bagarry-Liegey D,Nicoara A, Daffaud F,et al.Individual dose adjustment of high-dose methotrexate in clinical practice[J]. Revue de Medicine Interne,1996,17(8):689
9[6]Yacigi A,Ezzat A.Pharmacokinetic monitoring of anticancer drugs at King Faisal specialist Hospital[J].Riyadh,Saudi Arabia.Therapeutic Drug Monitoring,1997，19(4):390
3[2]Yu YP,Guo GY.One case:report about HDMTX cause central nervous system toxic to death[J].Leukemia,1998,7(2):67.
4[4]Rule G,Chapple M,Henion J.A 384-well solid-phase extraction for LC-MS-MS determination of methotrexate and its 7-hydroxy metabolite in human urine and plasma[J].Rule.Anal.Chern,2001,73 (3):439-443.
5Rule G,Chapple M,Henion J.A 384-well solid-phase extraction for LC-MS-MS determination of methotrexate and its 7-hydroxy metabolite in human urine and plasma.Rule Anal Chem,2001,73(3):439-443.
